Table 4.
Oncological outcomes of patients who underwent RC and achieved or not pentafecta.
| RC-pentafecta achievement | |||||||
|---|---|---|---|---|---|---|---|
| Total | No | Yes | |||||
| No./mean | %/IQR | No./mean | %/IQR | No./mean | %/IQR | ||
| Staging T | 0.001 | ||||||
| pT0 | 22 | 7.24 | 17 | 7.17 | 5 | 7.46 | |
| pT1 | 36 | 11.84 | 23 | 9.70 | 13 | 19.40 | |
| pT2 | 85 | 27.96 | 61 | 25.74 | 24 | 35.82 | |
| pT3 | 80 | 26.32 | 67 | 28.27 | 13 | 19.40 | |
| pT4 | 54 | 17.76 | 52 | 21.94 | 2 | 2.99 | |
| CIS | 19 | 6.25 | 12 | 5.06 | 7 | 10.45 | |
| Ta | 8 | 2.63 | 5 | 2.11 | 3 | 4.48 | |
| MIBC | 219 | 72.04 | 180 | 75.95 | 39 | 58.21 | 0.006 |
| pT3–4 | 134 | 44.08 | 119 | 50.21 | 15 | 22.39 | <0.0001 |
| pN | |||||||
| pN0 | 206 | 67.76 | 151 | 63.71 | 55 | 82.09 | 0.007 |
| pN1 | 42 | 13.82 | 35 | 14.77 | 7 | 10.45 | |
| pN2 | 25 | 8.22 | 22 | 9.28 | 3 | 4.48 | |
| pN3 | 7 | 2.3 | 5 | 2.11 | 2 | 2.99 | |
| pNx | 24 | 7.89 | 24 | 10.13 | 0 | 0.00 | |
| Histology type | |||||||
| Pure urothelial | 263 | 86.51 | 211 | 89.03 | 52 | 77.61 | 0.024 |
| Other | 41 | 13.49 | 26 | 10.97 | 15 | 22.39 | |
| Pentafecta components | |||||||
| 12-month RFS* | 197 | 64.8 | 130 | 57.78 | 67 | 100.00 | <0.0001 |
| LND ≥ 10* | 143 | 47.04 | 76 | 32.07 | 67 | 100.00 | <0.0001 |
| Negative SM* | 266 | 87.5 | 199 | 83.97 | 67 | 100.00 | <0.0001 |
| Oncological outcomes | |||||||
| Recurrence | 106 | 34.87 | 105 | 45.85 | 1 | 1.49 | <0.0001 |
| Overall mortality | 105 | 34.54 | 103 | 43.64 | 2 | 2.99 | <0.0001 |
| Cancer-specific mortality | 81 | 26.64 | 80 | 33.76 | 1 | 1.49 | <0.0001 |
RC, radical cystectomy; IQR, interquartile range; CIS, carcinoma in situ; MIBC, muscle-invasive bladder cancer; RFS, recurrence-free survival; LND, lymph node density.
*Pentafecta variables.
SM, surgical margin.